CY1125465T1 - Σελαδελπαρη για αγωγη της πρωτοπαθους χολικης χολαγγειιτιδας - Google Patents

Σελαδελπαρη για αγωγη της πρωτοπαθους χολικης χολαγγειιτιδας

Info

Publication number
CY1125465T1
CY1125465T1 CY20221100534T CY221100534T CY1125465T1 CY 1125465 T1 CY1125465 T1 CY 1125465T1 CY 20221100534 T CY20221100534 T CY 20221100534T CY 221100534 T CY221100534 T CY 221100534T CY 1125465 T1 CY1125465 T1 CY 1125465T1
Authority
CY
Cyprus
Prior art keywords
treatment
seladelpari
primary biliary
biliary cholangitis
cholangitis
Prior art date
Application number
CY20221100534T
Other languages
Greek (el)
English (en)
Inventor
Charles A. Mcwherter
Pol Boudes
Original Assignee
Cymabay Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics, Inc. filed Critical Cymabay Therapeutics, Inc.
Publication of CY1125465T1 publication Critical patent/CY1125465T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20221100534T 2016-05-31 2022-08-04 Σελαδελπαρη για αγωγη της πρωτοπαθους χολικης χολαγγειιτιδας CY1125465T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31

Publications (1)

Publication Number Publication Date
CY1125465T1 true CY1125465T1 (el) 2025-05-09

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100534T CY1125465T1 (el) 2016-05-31 2022-08-04 Σελαδελπαρη για αγωγη της πρωτοπαθους χολικης χολαγγειιτιδας

Country Status (27)

Country Link
US (5) US10272058B2 (OSRAM)
EP (1) EP3463328B1 (OSRAM)
JP (1) JP7079735B2 (OSRAM)
KR (1) KR102408288B1 (OSRAM)
CN (1) CN109195594A (OSRAM)
AU (1) AU2017274293B2 (OSRAM)
BR (1) BR112018074147A2 (OSRAM)
CA (1) CA3024155C (OSRAM)
CY (1) CY1125465T1 (OSRAM)
DK (1) DK3463328T3 (OSRAM)
ES (1) ES2921230T3 (OSRAM)
HR (1) HRP20220903T1 (OSRAM)
HU (1) HUE059838T2 (OSRAM)
IL (1) IL263372B2 (OSRAM)
LT (1) LT3463328T (OSRAM)
MX (1) MX390417B (OSRAM)
NZ (1) NZ748721A (OSRAM)
PL (1) PL3463328T3 (OSRAM)
PT (1) PT3463328T (OSRAM)
RS (1) RS63345B1 (OSRAM)
RU (1) RU2765460C2 (OSRAM)
SG (1) SG11201810123SA (OSRAM)
SI (1) SI3463328T1 (OSRAM)
SM (1) SMT202200471T1 (OSRAM)
UA (1) UA122719C2 (OSRAM)
WO (1) WO2017209865A1 (OSRAM)
ZA (1) ZA201808360B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR20210092754A (ko) * 2018-11-16 2021-07-26 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash의 병용 치료
HUE066653T2 (hu) * 2021-02-01 2024-08-28 Cymabay Therapeutics Inc Cholangiopathiák kezelése seladelparral

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
AU5359496A (en) 1995-03-06 1996-09-23 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
ATE267207T1 (de) 1996-02-14 2004-06-15 Isis Pharmaceuticals Inc Kohlenhydratmodifizierte luckenhafte oligonukleotide
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
PL1667964T3 (pl) 2003-09-19 2010-01-29 Janssen Pharmaceutica Nv Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
DK1725234T4 (en) 2004-03-05 2016-05-09 Univ Pennsylvania METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
MX2011004077A (es) 2008-10-17 2011-08-17 Metabolex Inc Metodos para reducir particulas de ldl densas, pequeñas.
NZ807894A (en) * 2009-04-29 2025-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AU2011235301B2 (en) 2010-03-30 2013-07-18 Novartis Ag Uses of DGAT1 inhibitors
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EP3071198A1 (en) 2013-11-20 2016-09-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
PL3129018T3 (pl) 2014-04-11 2020-05-18 Cymabay Therapeutics, Inc. Leczenie NAFLD i NASH
SG11201610243YA (en) 2014-06-26 2017-01-27 Cymabay Therapeutics Inc Treatment of severe hypertriglyceridemia
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
WO2019067373A1 (en) 2017-09-26 2019-04-04 Cymabay Therapeutics, Inc. TREATMENT OF CHOLESTATIC PRURIT
MX2021005725A (es) 2018-11-16 2021-07-21 Cymabay Therapeutics Inc Tratamiento de la obesidad y sus complicaciones.
KR20210092754A (ko) 2018-11-16 2021-07-26 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash의 병용 치료

Also Published As

Publication number Publication date
SG11201810123SA (en) 2018-12-28
BR112018074147A2 (pt) 2019-03-06
WO2017209865A1 (en) 2017-12-07
US20200061006A1 (en) 2020-02-27
IL263372A (en) 2018-12-31
ES2921230T3 (es) 2022-08-22
US20210000774A1 (en) 2021-01-07
LT3463328T (lt) 2022-08-10
SI3463328T1 (sl) 2022-08-31
US10813895B2 (en) 2020-10-27
DK3463328T3 (da) 2022-07-04
MX2018014915A (es) 2019-04-24
US20170340589A1 (en) 2017-11-30
US10478411B2 (en) 2019-11-19
PL3463328T3 (pl) 2022-10-03
US11000494B2 (en) 2021-05-11
KR102408288B1 (ko) 2022-06-10
US20210220305A1 (en) 2021-07-22
AU2017274293A1 (en) 2018-12-13
NZ748721A (en) 2022-04-29
AU2017274293B2 (en) 2022-03-31
JP7079735B2 (ja) 2022-06-02
CA3024155C (en) 2023-10-10
JP2019518022A (ja) 2019-06-27
RU2018146504A3 (OSRAM) 2020-07-27
PT3463328T (pt) 2022-07-07
CN109195594A (zh) 2019-01-11
RS63345B1 (sr) 2022-07-29
SMT202200471T1 (it) 2023-01-13
HUE059838T2 (hu) 2023-01-28
US20190255004A1 (en) 2019-08-22
CA3024155A1 (en) 2017-12-07
ZA201808360B (en) 2020-02-26
RU2765460C2 (ru) 2022-01-31
HRP20220903T1 (hr) 2022-10-14
RU2018146504A (ru) 2020-07-09
UA122719C2 (uk) 2020-12-28
US11596614B2 (en) 2023-03-07
US10272058B2 (en) 2019-04-30
MX390417B (es) 2025-03-20
EP3463328B1 (en) 2022-06-15
EP3463328A1 (en) 2019-04-10
KR20190015363A (ko) 2019-02-13
IL263372B2 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
CY1125465T1 (el) Σελαδελπαρη για αγωγη της πρωτοπαθους χολικης χολαγγειιτιδας
CY1120927T1 (el) Αγωγη των ενδοηπατικων χολοστατικων νοσων
CY1124894T1 (el) Θεραπευτικη αντιμετωπιση χολοστατικου κνησμου με σελαδελπαρη
IL268709A (en) Radiation source
EP3398564A4 (en) LUMINOUS STENT
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3289832T3 (da) Opgradering af lyskilde
EP3563802A4 (en) LUMINAL STENT
EP3360010A4 (en) BI PHOTONS WITH VOTABLE SOURCE
EP3302356A4 (en) BALLOON-SUPPORTED RELEASE OF AN ENDOLUMINAL PROTECTION
DK3488443T3 (da) Udvælgelse af neoepitoper som sygdomsspecifikke mål for terapi med øget virkning
EP3378442C0 (en) IMPROVED ACCOMMODATIVE INTRAOCULAR LENS
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK2897382T3 (da) Forbedring af binaural kilde
DK3688530T3 (da) Strålingskilde
EP3733127A4 (en) LUMINAL STENT
IL258631B (en) Plasma based light source having a target material coated on a cylindrically-symmetric element
DK3289875T3 (da) Anvendelse af plantesygdomsbekæmpelsesmidler
FR3037712B1 (fr) Methode de realisation de motifs par implantation
EP3509452A4 (en) ANKLE REST
DK3855181T3 (da) Forbindelser til behandling af lipofuscinrelaterede sygdomme
EP3991753A4 (en) Transfection method
IT201700100732A1 (it) Sorgente ionica
EP3625597C0 (en) Coherent single photon source
EP3515376C0 (en) ANKLE SUPPORT